LYN and chronic myelogenous leukemia, BCR-ABL1 positive: It is also very interesting to note that the second generation (T315I non-effective, e.g. Dasatinib [94] and Bafetinib [95]) and third generation (T315I effective, e.g. Ponatinib [96]) anti-CML drugs, predominantly developed to combat the different point mutations in BCR-Abl that are the more common causes of Imatinib resistance, are also potent and effective inhibitors of Lyn [12].